BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/21/2018 1:32:15 AM | Browse: 815 | Download: 1298
Publication Name World Journal of Clinical Oncology
Manuscript ID 39252
Country/Territory India
Received
2018-06-16 14:21
Peer-Review Started
2018-06-17 12:51
To Make the First Decision
2018-07-19 07:45
Return for Revision
2018-07-23 03:07
Revised
2018-08-24 09:02
Second Decision
2018-11-01 02:25
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2018-11-04 20:25
Articles in Press
2018-11-04 20:25
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2018-12-17 03:15
Publish the Manuscript Online
2018-12-21 01:32
ISSN 2218-4333 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Basic Study
Article Title Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model
Manuscript Source Invited Manuscript
All Author List Himani Garg, Rohit Singh Hada, Jagdish C Gupta, G P Talwar and Shweta Dubey
ORCID
Author(s) ORCID Number
Himani Garg http://orcid.org/0000-0002-4672-8289
Rohit Singh Hada http://orcid.org/0000-0002-3236-3047
Jagdish C Gupta http://orcid.org/0000-0002-9456-0097
G P Talwar http://orcid.org/0000-0002-3421-1303
Shweta Dubey http://orcid.org/0000-0002-0457-9692
Funding Agency and Grant Number
Funding Agency Grant Number
Science and Engineering Research Board under the Department of Science and Technology, Govt of India SR/FT/LS-75/2012
Science and Engineering Research Board under the Department of Science and Technology, Govt of India SB/SO/HS/062/2013
Corresponding Author Shweta Dubey, PhD, Associate Professor, Amity Institute of Virology and Immunology, Amity University Uttar Pradesh, J-3 Block, Room No: LG21, Sector 125, Noida 201303, Uttar Pradesh, India. sdubey@amity.edu
Key Words Immunotherapy; Survivin; Luteinizing hormone-releasing hormone fusion protein; Combination immunotherapy; Breast cancer
Core Tip Targeting Survivin for treatment of cancer is an emerging trend in cancer immunotherapy. In this study we optimized the dose of recombinant full-length Survivin for tumor growth inhibition. Since luteinizing hormone-releasing hormone (LHRH) is also known to support breast cancer in case of premenopausal women, we combined recombinant LHRH fusion protein with Survivin and Mycobacterium indicus pranii and obtained a positive anti-tumor response. We report our results of using recombinant Survivin protein and LHRH fusion protein as potential vaccine antigens for immunotherapy of murine model of breast cancer which was developed by injecting 4T-1 mammary cell line in syngeneic Balb/c mice. Immunized mice challenged with syngeneic 4T-1 cells exhibited suppression of tumor growth and metastasis in lungs in comparison to control mice.
Publish Date 2018-12-21 01:32
Citation Garg H, Hada RS, Gupta JC, Talwar GP, Dubey S. Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model. World J Clin Oncol 2018; 9(8): 188-199
URL https://www.wjgnet.com/2218-4333/full/v9/i8/188.htm
DOI https://dx.doi.org/10.5306/wjco.v9.i8.188
Full Article (PDF) WJCO-9-188.pdf
Full Article (Word) WJCO-9-188.doc
The ARRIVE Guidelines 39252-The ARRIVE Guidelines.pdf
Manuscript File 39252-Review.docx
Answering Reviewers 39252-Answering reviewers.pdf
Audio Core Tip 39252-Audio core tip.mp3
Biostatistics Review Certificate 39252-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 39252-Conflict-of-interest statement.pdf
Copyright License Agreement 39252-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 39252-Grant application form(s).pdf
Institutional Animal Care and Use Committee Approval Form or Document 39252-Institutional animal care and use committee statement.pdf
Institutional Review Board Approval Form or Document 39252-Institutional review board statement.pdf
Peer-review Report 39252-Peer-review(s).pdf
Scientific Misconduct Check 39252-Scientific misconduct check.pdf
Scientific Editor Work List 39252-Scientific editor work list.pdf